‘This marks a significant milestone in our global commercialisation strategy.’Proteomics International managing director Dr Richard Lipscombe More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation’s Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: “We’re excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.” The PromarkerD rollout will begin in California, supported by the company’s recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International’s integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement. Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test “a paradigm shift in diabetes care.” Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.